A new article out today sheds new light on the potential for differences in the way individual patients react to rectal cancer treatment. Acredit member Sebastian Meltzer’s study into the differences between blood profiles of patients with tumours with varying levels of aggressiveness shows that the patients showing the best prognosis may be the same ones who are able to activate their immune systems more readily. Dr Meltzer hopes that the identification of these biomarkers in the blood of patients will help physicians develop better treatment methods for patients with more resistant tumour burdens.
Read more about Sebastian’s study here. (in Norwegian)